Mondego Bio Announces Selection of a PTPN2 Inhibitor Clinical Candidate and Targets First-in-Human Trials in H1 2026
PR Newswire —
CANTANHEDE, Portugal, Dec. 22, 2025 /PRNewswire/ -- Mondego Bio, a clinical-stage biotechnology company developing next-generation small-molecule immuno-oncology therapies, today announced the formal selection of its lead clinical candidate, ZE00-0388, a highly selective inhibitor of...